Results 31 to 40 of about 2,383 (91)

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients. [PDF]

open access: yesMed, 2023
Bruel T   +24 more
europepmc   +1 more source

A relevância da metáfora visual para a memorização de um logótipo [PDF]

open access: yes, 2019
: We investigate visual metaphor (visual symbolism) in logotypes, its perception and its effect on memory. Henceforth, a visual standard experiment was developed for that effect. This model can be adapted to other logotypes (fig.4 and fig.6).
Almeida, Flávio de   +2 more
core  

Outcomes of Omicron sub-lineages BA.1.1 and BA.2 infection compared with the sub-lineage BA.1 infection in emergency departments' patients. [PDF]

open access: yesClin Microbiol Infect, 2023
Bouzid D   +23 more
europepmc   +1 more source

Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments : A Retrospective Cohort Study. [PDF]

open access: yesAnn Intern Med, 2022
Bouzid D   +19 more
europepmc   +1 more source

Un recueil parisien de psaumes, de chansons spirituelles et de motets (ca. 1565) : Genève BGE Ms. Mus. 572. [PDF]

open access: yes, 2012
International audienceStudy of the musical manuscript MS MUS 572, Bibliothèque de Genève. This volume, of Parisian origin, is written around 1567 and contains psalms (translated by Marot and Bèze), spiritual songs and motets.
Guillo, Laurent   +2 more
core   +1 more source

Les causes de la Réforme : une question reposée [PDF]

open access: yes, 1999
On s'est beaucoup interrogé sur le pourquoi de la Réforme et les réponses n'ont pas manqué, mettant en œuvre l'histoire politique, l'histoire économique, l'histoire sociale, ou socio-culturelle, de l'Occident au XVIe siècle, et plusieurs de ces réponses ...
Wanegffelen, Thierry
core   +1 more source

Time to negative PCR conversion amongst high-risk patients with mild-to-moderate Omicron BA.1 and BA.2 COVID-19 treated with sotrovimab or nirmatrelvir. [PDF]

open access: yesClin Microbiol Infect, 2023
Martin-Blondel G   +33 more
europepmc   +1 more source

Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). [PDF]

open access: yesJ Infect, 2022
Martin-Blondel G   +14 more
europepmc   +1 more source

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. [PDF]

open access: yesJ Infect, 2022
Martin-Blondel G   +30 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy